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Abstract
Background: Serum gamma-glutamyl transferase (GGT) is a marker 
of oxidative stress, associated with increased cardiovascular (CV) 
risk. The impact of smoking on oxidative stress may be aggravated 
in individuals with non-alcoholic fatty liver disease (NAFLD). We 
aimed to ascertain the association of smoking on GGT levels in the 
presence or absence of NAFLD.
Methods: We evaluated 6,354 healthy subjects (43 ± 10 years, 79% 
males) without clinical cardiovascular disease (CVD) undergoing an 
employer-sponsored physical between December 2008 and Decem-
ber 2010. NAFLD was diagnosed by ultrasound and participants were 
categorized as current or non-smokers by self report. A multivariate 
linear regression of the cross-sectional association between smoking 
and GGT was conducted based on NAFLD status.
Results: The prevalence of NAFLD was 36% (n = 2,299) and 564 
(9%) were current smokers. Smokers had significantly higher GGT 
levels in the presence of NAFLD (P < 0.001). After multivariable 
adjustment, current smoking was associated with 4.65 IU/L higher 
GGT level, P < 0.001, compared to non-smokers. When stratified by 
NAFLD, the magnitude of this association was higher in subjects 
with NAFLD (β-coefficient: 11.12; 95% confidence interval (CI): 
5.76 - 16.48; P < 0.001); however, no such relationship was observed 
in those without NAFLD (β: -0.02; 95% CI: -3.59, 3.56; P = 0.992). 
Overall the interaction of NAFLD and smoking with GGT levels as 
markers of oxidative stress was statistically significant.
Conclusions: Smoking is independently associated with significantly 
increased oxidative stress as measured by GGT level. This association 
demonstrates effect modification by NAFLD status, suggesting that 
smoking may intensify CV risk in individuals with NAFLD.
Keywords: Gamma-glutamyl transferase; Oxidative stress; Non-al-
coholic fatty liver disease; Smoking; Cardiovascular risk
Introduction
Oxidative stress plays a crucial role in cardiovascular disease 
(CVD) mediating the pathway to atherosclerosis and inflam-
mation [1, 2]. The oxidative stress theory is based on the as-
sumption that the initial phase of atherosclerosis is dependent 
on low-density lipoprotein (LDL) oxidative modifications [3].
Gamma-glutamyl transferase (GGT) is a biomarker se-
creted mostly by the liver and found in epithelial cells of hu-
mans. It plays an important role in glutathione metabolism, an 
important component of the anti-oxidative process [4, 5]. This 
marker has been implicated in atherosclerosis, diabetes, meta-
bolic syndrome and increased cardiovascular (CV) risk [6-16]. 
Elevated GGT levels have also been linked with hepatic stea-
tosis (HS) and liver cancer [14, 17]. While non-alcoholic fatty 
liver disease (NAFLD) is the leading cause of chronic liver 
disease in the western world, evidence has also shown it as an 
independent risk factor for CVD [18, 19].
Similarly, it has been established that cigarette smoking 
is an important risk factor for atherosclerosis and associated 
with significant vascular disease [20-23]. Smoking enhances 
the production of reactive oxygen species which promotes oxi-
dative stress and lipid peroxidation [24-27]. While smoking is 
associated with oxidative stress, its influence on GGT levels 
in individuals with NAFLD is not clearly defined. Our study 
examines the effect of the presence of NAFLD on the associa-
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tion between smoking and oxidative stress by GGT levels in an 
asymptomatic population.
Materials and Methods
A total of 6,354 asymptomatic men and women, free of CVD, 
who had an obligatory clinical and laboratory health evalua-
tion from December 2008 to December 2010 at the Preventive 
Medicine Center of the Albert Einstein Hospital in Sao Paulo, 
Brazil were evaluated. The examination protocol has been pre-
viously described in prior publications [28]. Individuals were 
provided with questionnaires for self-reported details of their 
demographics, medical history, quantitative alcohol consump-
tion, smoking status and medication usage during their clinical 
visits. We excluded 110 individuals with missing information 
of either smoking status, GGT levels and presence of steatosis. 
Individuals with an established history of liver disease were 
also excluded. Individual smoking status was defined as ei-
ther current smoker or non-smoker. While current smoker was 
defined as smoking at least one cigarette in the last 1 month, 
non-smoker was one who did not smoke in the last month. Dia-
betes mellitus was identified by a previous physician diagnosis 
or the use of glucose-lowering medication. Hypertension and 
dyslipidemia were ascertained by a previous history or the use 
of medications. Blood pressure measurements were made us-
ing an aneroid sphygmomanometer using the recommended 
method from the American Heart Association [29]. The waist 
circumference was the smallest diameter between the iliac 
crest and the costal margin using a plastic anthropometric tape.
All blood specimens were collected after an overnight 
fast. Plasma lipid, glucose, GGT and liver transaminase levels 
(alanine aminotransferase (ALT) and aspartate aminotrans-
ferase (AST)) levels were measured by standardized automat-
ed laboratory tests using a Vitros platform (Johnson & Johnson 
Clinical Diagnostics, New Brunswick, New Jersey). High-sen-
sitivity C-reactive protein (hs-CRP) levels were determined 
by immunonephelometry (Dade-Behring GMbH, Mannhein, 
Germany). All tests were performed at the Central Laboratory 
of the Albert Einstein Hospital.
NAFLD was diagnosed after at least a 6-h fast using an 
ACUSON XP-10 device (Mountain View, CA) and was identi-
fied by the presence of an ultrasonographic pattern of a bright 
liver, with evident contrast between hepatic and renal paren-
chyma and using a standardized algorithm (indicating HS) [30, 
31]. Obesity was defined as a body mass index (BMI) of greater 
than 30 kg/m2. The metabolic syndrome (MS) was defined using 
criteria from the American Heart Association/National Heart, 
Lung, and Blood Institute published scientific statement on the 
metabolic syndrome [32]. Patients with ≥ 3 of the following 
risks were classified as having the MS: truncal obesity (≥ 102 
cm (40 inches) for men and ≥ 88 cm (36 inches) for women), 
high blood pressure (blood pressure ≥ 130/85 mm Hg or the use 
of antihypertensive medications), hyperglycemia (fasting blood 
glucose ≥ 100 mg/dL), low high-density lipoprotein cholesterol 
(HDL-C) (≤ 40 mg/dL for men and ≤ 50 mg/dL for women) 
and hypertriglyceridemia (≥ 150 mg/dL) [32]. This study did not 
involve any animal study and appropriate IRB approval was ob-
tained prior to the administration of surveys to the participants. 
All data were de-identified prior to analysis and determined not 
to meet criteria for protected health information (PHI) [28].
Baseline characteristics of individuals with a combination 
of the presence or absence of NAFLD and smoking status was 
compared using the analysis of variance test for continuous 
variables and the Pearson’s χ2 test for categorical variables. The 
non-parametric Kruskal-Wallis test was used to compare the 
median of variables with skewed distribution (ALT, AST, GGT 
and hs-CRP). A multivariate linear regression was used to eval-
uate associations of smoking and GGT levels. The regression 
analysis was done by stratifying the presence of NAFLD and 
obesity to ascertain an independent association. For all regres-
sion analyses, a hierarchical model approach was used, adjust-
ing first for age and gender and then simultaneously adjusting 
for other confounding factors (waist circumference, triglycer-
ides, HDL-C, systolic blood pressure (SBP), fasting glucose, 
LDL-C, CRP, lipid lowering and antihypertensive medications 
and alcohol use). Alcohol use was quantified by the alcohol use 
disorders identification test (AUDIT) score [33]. The AUDIT 
score was developed and validated by the World Health Or-
ganization among men and women in different countries. We 
categorized a total AUDIT score of ≥ 8 as high alcohol con-
sumption for men and ≥ 4 for women [34]. A model including 
an interaction term for HS and smoking was fitted to assess 
whether smoking modified the association between HS and 
GGT. All statistical analyses were performed using STATA sta-
tistical software, release 12 (College Station, TX).
Results
The characteristics of the study population were stratified by 
the combination of smoking status and the presence of NAFLD 
(Table 1). There were 6,354 subjects analyzed: 3,731 (59%) 
non-smokers without NAFLD, 2,060 (32%) non-smokers who 
had NAFLD, 324 (5%) smokers without NAFLD and 239 (4%) 
smokers with NAFLD. There were statistically significant dif-
ferences in demographics, anthropometric and biochemical 
profiles between the four groups. Individuals with NAFLD 
were more likely to be men, older and have a higher burden of 
risk factors (Table 1). However, smoking combined with the 
presence of NAFLD further worsened this association. Smok-
ers with NAFLD had the highest prevalence of the MS.
Smokers with NAFLD were more likely to have the high-
est level of GGT levels (P < 0.001). Individuals who smoked 
and had NAFLD had the highest median levels compared to 
individuals who had NAFLD alone, smoked without NAFLD 
or were non-smokers without NAFLD. Figures 1 and 2 show 
the effect of smoking on the GGT levels in the presence and 
absence of NAFLD. Although the presence of NAFLD alone 
was associated with a high GGT level, it was even higher when 
the presence of NAFLD is combined with a positive smoking 
status (Fig. 1). Figure 2 shows similar effect of cigarette smok-
ing on the quartiles of GGT levels when stratified by the pres-
ence of NAFLD. While non-smokers without NAFLD have 
predominantly GGT levels in the lowest quartiles, there is a 
steady redistribution to the higher quartiles in smokers with-
out NAFLD, non-smokers with NAFLD and smokers with 
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NAFLD. The GGT levels in smokers with NAFLD were pre-
dominately in the highest quartile. Figure 3 presents a similar 
relationship when stratified by MS.
Table 2 presents multivariate regression of the relation-
ship between smoking and serum GGT levels. The results are 
presented from both the unadjusted and adjusted models for 
possible confounders. The analysis was also stratified by the 
presence of NAFLD. While there was a significant relationship 
between smoking and GGT in both the combined population 
and among individuals with NAFLD, the association was how-
ever not significant when NAFLD was absent. In the combined 
population, the GGT level of smokers was 4.65 IU/L higher. It 
was higher among individuals with NAFLD in the stratified 
analysis, as the GGT level of smokers in this group was 11.12 
IU/L higher. The model testing for interaction demonstrated a 
statistically significant interaction of NAFLD and smoking in 
the association of smoking on GGT levels. We also found a 
similar association when stratified by the presence of obesity 
(Table 3). Obesity interacted with the association of smoking 
and the GGT levels and we noted the effect of smoking on 
GGT was independent of gender (Fig. 4).
Discussion
Our study of 6,354 asymptomatic individuals assessed the im-
pact of smoking on oxidative stress in NAFLD. While 9% of 
the population were smokers, 36% had NAFLD. We demon-
strated the presence of NAFLD modified the impact of ciga-
rette smoking on GGT levels. Smokers who had NAFLD had 
higher GGT levels with evidence of interaction between smok-
ing and NAFLD on the effect of smoking on GGT levels. This 
effect modification was also demonstrated with obesity and 
independent of gender.
This findings support prior studies that showed a relation-
ship between smoking, NAFLD and GGT levels [24, 35, 36]. 
Smoking promotes oxidative stress and has a role in the devel-
opment and progression of NAFLD [24]. While liver fat is a 
useful measure of visceral adiposity, it is also associated with 
increased risk of CVD [19-21].
Cigarette smoking has enormous consequences on health. 
It has been implicated in the development of NAFLD and 
known to cause inflammation and oxidative stress. It affects in-
Figure 1. Box plot of GGT levels by the combination of smoking status and presence of HS. GGT: gamma-glutamyl transferase; 
HS: hepatic steatosis.
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sulin resistance (IR) [35, 37, 38], which may play a role in the 
development/progression of HS, a component of NAFLD [24]. 
Importantly, it has been demonstrated that smoking is a risk 
factor for glucose intolerance and diabetes [39-41]. NAFLD 
pathogenesis has been linked to IR and the promotion of stea-
togenesis by increasing the availability of free fatty acids and 
glucose from adipose tissue and excess dietary intake. This 
increases de novo hepatic lipogenesis, decrease fatty acid oxi-
Figure 2. Distribution of GGT quartiles by smoking status and presence of NAFLD. GGT: gamma-glutamyl transferase; NAFLD: 
non-alcoholic fatty liver disease.
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dation and decrease release of lipids from hepatocytes into cir-
culation [18, 42]. Hamabe et al reported cigarette smoking was 
an independent risk factor for the onset of HS [24]. This study 
was supported by Lui et al, who reported that passive smoking 
and heavy active smoking were both associated with prevalent 
HS [36]. In a cross-sectional study subjects with NAFLD who 
smoked had a higher frequency of the MS compared to sub-
jects with NAFLD who did not smoke [43]. Experimental data 
have also reported that smoking could worsen liver injury in 
NAFLD [44]. Smoking encourages the production of activated 
NADPH oxidase-induced reactive species, which enhances 
oxidative stress and lipid peroxidation [24]. Oxidative stress is 
a known mechanism of injury in HS [35, 45]. This study shows 
that smoking increased GGT levels in general and much more 
among persons with HS. As expected a similar relationship 
was seen with MS and obesity. Our finding supports previous 
studies that have shown that smokers had higher GGT levels 
[46-48].
GGT is an enzyme responsible for the extracellular catab-
olism of the antioxidant glutathione [49, 50]. Although used 
as a diagnostic marker for hepato-bilary disease and alcohol 
abuse, strong epidemiological and clinical evidence suggests 
that serum GGT is a potential biomarker for CV morbidity and 
mortality [51]. Population studies reported significant inde-
pendent associations between serum GGT concentrations and 
risk factors, like hypertension, type 2 diabetes and stroke in-
dependent of alcohol consumption [6, 8, 10, 15, 52]. Although 
the mechanism of this association is not clearly defined, it is 
likely related to oxidative stress [49, 53], which could be due 
to the GGT-linked pro-oxidant effect of glutathione catabolism 
Figure 3. Distribution of GGT quartiles by smoking status and presence of metabolic syndrome. GGT: gamma-glutamyl trans-
ferase.
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[49]. GGT notably participates in the proliferation of ather-
omatous plaques [50] and it is believed that oxidative stress 
may be the mediating factor of the association between GGT 
levels and CVD through atherosclerosis [49, 53]. GGT plays 
a key role in maintaining intracellular anti-oxidant systems 
through its mediation of extracellular glutathione transport into 
cells. The association of elevated GGT with CVD is remark-
able; Wannamethee et al described a significant relationship 
Figure 4. β-coefficient of the linear regression of smoking and GGT level stratified by gender. GGT: gamma-glutamyl transferase.
Table 2.  Linear Regression of the Association Between Smoking and GGT Level Stratified by NAFLD
Total (standard-





Model 1 6.83 (3.69 - 9.96)*** 10.31 (4.68 - 15.95)*** 2.36 (-1.14 - 5.85) P = 0.012
Model 2 6.51 (3.46 - 9.56)*** 10.19 (4.57 - 15.81)*** 2.57 (-0.83 - 5.9) P = 0.015
Model 3 4.65 (1.61 - 7.69)** 11.12 (5.76 - 16.48)*** -0.02 (-3.59 - 3.56) P < 0.001
*P < 0.05, **P < 0.005, ***P < 0.001. Model 1: unadjusted. Model 2: adjusted for age, gender. Model 3: model 2 + SBP, waist circumference, fasting 
glucose, lipid lowering medications, hypertension meds, LDL-C, AST, alcohol consumption and C-reactive protein. GGT: gamma-glutamyl trans-
ferase; NAFLD: non-alcoholic fatty liver disease; HS: hepatic steatosis; SBP: systolic blood pressure; LDL-C: low-density lipoprotein cholesterol; 
AST: aspartate aminotransferase.
Table 3.  Linear Regression of the Association Between Smoking and GGT Level Stratified by Obesity
Obesity+ (standardized coefficient) Obesity- (standardized coefficient) Interaction (obesity-smoking)
Model 1 11.14 (3.24 - 19.03)* 4.65 (1.43 - 7.87)* P = 0.072
Model 2 10.46 (2.64 - 18.27)* 4.60 (1.48 - 7.73)** P = 0.096
Model 3 12.73 (5.5 - 19.96)** 1.74 (-1.45 - 4.94) P < 0.001
*P < 0.05, **P < 0.005, ***P < 0.001. Model 1: unadjusted. Model 2: adjusted for age, gender. Model 3: model 2 + SBP, fasting glucose, lipid lowering 
medications, hypertension meds, LDL-C, AST, alcohol consumption and C-reactive protein. GGT: gamma-glutamyl transferase; SBP: systolic blood 
pressure; LDL-C: low-density lipoprotein cholesterol; AST: aspartate aminotransferase.
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between GGT and CV events in a large prospective study with 
follow-up up to 24 years [54]. Furthermore, increased GGT 
levels have been demonstrated to be connected to coronary ar-
tery stenoses [1, 9]. GGT forms complexes with lipoprotein 
within atheromatous lesions and in plaques [9, 50].
However, there are questions whether the CV risk of in-
creased GGT is modifiable [1]. Although there is no convinc-
ing evidence that risk for CV events is lessened by decreasing 
GGT, there are existing reports of the use of fibrates reducing 
GGT concentrations in individuals with hypertriglyceridem-
ia, improving their lipid profile [55, 56]. This may be related 
to the role of fatty liver in generating increased serum GGT 
and its association with an increased CV risk [1, 57]. Since 
NAFLD is mostly treated by life style modifications, serum 
GGT levels could also be modifiable through these measures.
Implications
Our study provides evidence that GGT, an increasingly rec-
ognized biomarker for CV risk, may be worsened by cigarette 
smoking in persons with non-alcoholic liver fat. This further 
re-enforces the importance of life style modifications among 
persons with NAFLD. Although the presence of NAFLD is an 
established risk for future CV morbidity and mortality, smoking 
provides additional insult to the liver and ultimately aggravates 
the risk. Since oxidative stress has been implicated in many 
disease processes, including inflammation and atherosclerosis, 
this study provides further motivation for physicians to empha-
size both screening for smoking and smoking cessation efforts 
in the routine care of individuals with HS and MS. Individuals 
with elevated GGT may be candidates for NAFLD screening.
Study limitations
There are a few limitations in this study. First, our study is 
cross-sectional and as such inferences are weakened as tem-
porality cannot be ascertained. Secondly, the classification of 
smoking status as current smoking and non-smoker did not 
provide any information on history of smoking and as such 
presents the challenge of a residual bias. Also, there was no in-
formation on the quantity of cigarettes smoked, as such a dose 
response association could not be verified. Thirdly, the number 
of smokers with HS compared to the rest of the population may 
be a limitation to the interpretation of the results. Fourthly, our 
diagnosis of liver fat was based on ultrasound findings. Al-
though ultrasound is a useful non-invasive and cheap tool for 
identifying NAFLD, its sensitivity for detecting fatty changes 
within the liver is reduced when less than moderate severity 
[28, 58]. Imaging using ultrasound is most effective when 
greater than a third of the liver is affected.
Strengths
Despite the limitations, this study has relevant strengths. An 
important strength for this study is the large number of par-
ticipants free of coronary heart disease. This has allowed for 
adjustment for multiple confounding risk factors to ascertain 
the relationship. The cohort size also allowed for evaluation 
of the relationship within demographic and clinical subgroups.
Conclusion
Oxidative stress plays a significant step in the development 
and progression of CVD. Serum GGT is an established and 
measurable biomarker of oxidative stress. In this study of 
asymptomatic individuals, smoking significantly raised oxi-
dative stress as measured by GGT level among persons with 
NAFLD. While elevated GGT levels are associated with both 
NAFLD and CVD risk, smoking may further worsen this risk. 
Although future longitudinal studies to ascertain this associa-
tion are imperative, this study provides further motivation for 
physicians to emphasize smoking screening and cessation in 
the routine care of individuals with NAFLD and MS.
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